重组AcHERV-杆状病毒疫苗诱导抗人诺如病毒的稳健免疫应答
本研究开发了基于AcHERV平台表达HuNoV VP1蛋白的重组杆状病毒疫苗AcHERV-HuNoV,并在BALB/c小鼠中经肌内和鼻内途径评估免疫原性。疫苗诱导了针对GII.4的血清IgG GMT达14132(95%CI:9080-21979)和IgA水平262(95%CI:70-982),并产生有效的替代中和活性及Th1、Th2、Th17细胞免疫应答。
要点
- AcHERV-HuNoV疫苗在小鼠中诱导高滴度特异性IgG和IgA抗体。
- 疫苗诱导了有效的替代中和活性及Th1/Th2/Th17细胞免疫。
- 该疫苗平台可同时诱导体液和细胞免疫,具候选疫苗潜力。
核心结论
- AcHERV-HuNoV疫苗在小鼠中诱导了稳健的体液和细胞免疫应答,展示作为HuNoV遗传疫苗候选的潜力。
研究设计与样本
- 研究开发表达HuNoV VP1蛋白的重组杆状病毒疫苗AcHERV-HuNoV,并在BALB/c小鼠中经肌内和鼻内途径评估免疫原性。
主要发现
- 最终免疫后血清GII.4特异性IgG GMT达14132(95%CI:9080-21979),IgA水平为262(95%CI:70-982)。
- 疫苗诱导了有效的替代中和活性,通过猪胃黏蛋白(PGM)阻断试验测定。
- 疫苗诱导了以Th1、Th2和Th17细胞因子产生增加为特征的稳健细胞免疫。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Human norovirus (HuNoV) is a leading global cause of acute viral gastroenteritis, placing a particularly high burden on pediatric and elderly populations. Despite significant progress in HuNoV vaccine development, including advanced clinical trials of virus-like particle (VLP)-based candidates, no vaccine has received regulatory approval to date. In this study, we developed a recombinant baculovirus-based vaccine, AcHERV-HuNoV, designed to express the human norovirus (HuNoV) VP1 protein. This vaccine utilizes the AcHERV platform, which consists of Autographa californica multiple nucleopolyhedrovirus (AcMNPV) with the human endogenous retrovirus (HERV) envelope protein to enhance delivery efficiency. The AcHERV-HuNoV vaccine incorporates HERV-W-derived Syncytin-1 on the baculovirus envelope and the VP1 gene from either the GII.4 or GII.17 genotype to represent prevalent strains in Korea. This system enhances gene delivery to mammalian cells while preventing in vivo replication. Norovirus VLPs were produced and purified from insect cells to serve as control vaccines and comparative antigens. Immunogenicity was evaluated in BALB/c mice following intramuscular and intranasal administration of AcHERV-HuNoV. The vaccine induced robust immune responses, with serum IgG geometric mean titers (GMTs) reaching 14,132 (95% CI: 9080-21,979) and IgA levels of 262 (95% CI: 70-982) specific for GII.4 after final immunization, as well as potent surrogate neutralizing activity determined by the porcine gastric mucin (PGM)-blocking assay. Furthermore, it induced robust cellular immunity characterized by increased production of Th1, Th2, and Th17 cytokines. These results demonstrate the promising potential of AcHERV-HuNoV as a genetic vaccine candidate capable of inducing both humoral and cellular immune responses against HuNoV infection.
引用
- Yoon D, Lee H, Lee Y, et al. Recombinant AcHERV-baculovirus vaccine elicits robust immune responses against human norovirus. Vaccine. 2026. PMID: 42066579. doi:10.1016/j.vaccine.2026.128641
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。